Comparative biodistribution and radiation dosimetry of 68Ga- DOTATOC and 68Ga-DOTATATE in patients with neuroendocrine tumors

Journal of Nuclear Medicine

Volumn 54, Issue 10, 2013, Pages 1755-1759

  Sandström, Mattias ^a,b   Velikyan, Irina ^a,b   Garske Román, Ulrike ^a,b   Sörensen, Jens ^a,b   Eriksson, Barbro ^a   Granberg, Dan ^a   Lundqvist, Hans ^a   Sundin, Anders ^c   Lubberink, Mark ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Biodistribution; Dosimetry; Neuroendocrine tumors

Indexed keywords

DOTATATE GA 68; DOTATOC GA 68; GALLIUM 68; UNCLASSIFIED DRUG; 68GA DOTATATE; 68GA-DOTATATE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; GA(III) DOTATOC; GA(III)-DOTATOC; OCTREOTIDE; ORGANOMETALLIC COMPOUND;

ADRENAL GLAND; ADULT; AGED; ARTICLE; BLADDER; CLINICAL ARTICLE; CONTROLLED STUDY; DOSIMETRY; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG LIVER LEVEL; DRUG UPTAKE; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY; MALE; NEUROENDOCRINE TUMOR; PET SCANNER; PRIORITY JOURNAL; RADIATION ABSORPTION; SPLEEN; WHOLE BODY CT; WHOLE BODY PET; 68GA-DOTATOC; BIODISTRIBUTION; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; METABOLISM; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON EMISSION TOMOGRAPHY; RADIOMETRY; SCINTISCANNING; TISSUE DISTRIBUTION; WHOLE BODY IMAGING; ANALOGS AND DERIVATIVES; DIAGNOSTIC USE;

68GA-DOTATATE; 68GA-DOTATOC; BIODISTRIBUTION; DOSIMETRY; NEUROENDOCRINE TUMORS;

ADULT; AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NEUROENDOCRINE TUMORS; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; RADIOMETRY; TISSUE DISTRIBUTION; TOMOGRAPHY, X-RAY COMPUTED; WHOLE BODY IMAGING;

EID: 84891720550     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.120600     Document Type: Article

References (15)

1. 68Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives. Semin Nucl Med. 2011;41:314-321.
2. 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. J Nucl Med. 2011;52:1864-1870.
3. 68Ga-DOTATOC PET/CT examinations [in German]. Nuklearmedizin. 2009;48:201-207.
4. 68Ga-DOTATATE [abstract]. J Nucl Med. 2012;53(suppl):330P.
5. 111In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2004;31:1257-1262.
6. 3-octreotide (SMT487): a phase 1 clinical study-pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging. 2003;30:510-518.
7. Herzog H, Tellmann L, Scholten B, Coenen HH, Qaim SM. PET imaging problems with the non-standard positron emitters yttrium-86 and iodine-124. Q J Nucl Med Mol Imaging. 2008;52:159-165.
8. 68Gabioconjugates with high specific radioactivity. Bioconjug Chem. 2004;15:554-560.
9. Watson CC. New, faster, image-based scatter correction for 3D PET. IEEE Trans Nucl Sci. 2000;47:1587-1594.
10. 3]octreotate. Eur J Nucl Med Mol Imaging. 2009;36:1138-1146.
11. Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 1996;37:538-546.
12. ICRP Publication 30: Limits for Intakes of Radionuclides by Workers. Ottawa, Canada: International Commission on Radiological Protection; 1980.
13. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023-1027.
14. U.S. Food and Drug Administration Web site. Code of Federal Regulations Title 21, Section 361.1: Radioactive drugs for certain research uses. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?FR5361.1. Revised April 1, 2013. Accessed July 25, 2013.
15. 68Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2008;35:72-79.